



Contact:

David Waldman or Justyna Gudaszezwska  
Crescendo Communications, LLC

Email: [mmd@crescendo-ir.com](mailto:mmd@crescendo-ir.com)

Tel: +48 693 354 580

**Milestone Medical Reports Video Interview with a Key Opinion Leader, Dr. Ayman A. Alian,  
Division Chief of Obstetric & Gynecological Anesthesiology at Yale School of Medicine**

*Interview features advantages of the CompuFlo® Epidural System and CathCheck™*

**ROSELAND, NJ, October 22, 2020 -- Milestone Medical Inc. (WAR:MMD)** today reported that Milestone Scientific Inc., the licensor of computer-controlled injection and drug delivery technology and the majority shareholder of Milestone Medical Inc. has published a video interview with a Key Opinion Leader, Dr. Ayman A. Alian, MBChB, Associate Professor of Anesthesiology and Division Chief of Obstetric & Gynecological Anesthesiology at the Yale School of Medicine.

The interview, which highlights the advantages of the CompuFlo® Epidural System and CathCheck™, is available at: <https://www.milestonescientific.com/news-media/presentations>

Dr. Alian discusses the benefits of the CompuFlo® Epidural System and CathCheck™, including verification of epidural placement during an epidural procedure and confirmation of catheter placement. Dr. Alian states, "It does improve the block. It does help you make a decision. It does decrease complications. It does decrease length of stay and improve patient satisfaction."

Arjan Haverhals, President of Milestone Scientific Inc., commented, "We are grateful to Dr. Alian for his leadership in adopting the CompuFlo® Epidural System and CathCheck™ as part of his practice. We believe the support from Dr. Alian and other anesthesiologists is further validation of our technology and advances us towards our goal of CompuFlo® and CathCheck™ becoming the new standard of care."

**About Milestone Scientific Inc.**

Milestone Scientific Inc. (MLSS) is a biomedical technology research and development company that patents, designs and develops innovative diagnostic and therapeutic injection technologies and instruments for medical, dental, cosmetic and veterinary applications. Milestone's computer-controlled systems are designed to make injections precise, efficient, and virtually painless. Milestone's proprietary DPS Dynamic Pressure Sensing technology® is our technology platform that advances the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, with specific applications for cosmetic botulinum toxin injections, epidural space identification in regional anesthesia procedures and intra-articular joint injections. For more information please visit our website: [www.milestonescientific.com](http://www.milestonescientific.com).

**About Milestone Medical Inc.**

Milestone Medical, Inc. has developed epidural and intra-articular drug delivery systems based on a patented, painless, computer-controlled injection and drug delivery technology originally developed by Milestone Scientific, Inc. Development of both the epidural and intra-articular instruments is now complete. The Company was granted the FDA marketing clearance of the epidural instrument in U.S. and is currently pursuing regulatory approval for intra-articular instrument in the U.S. Milestone Medical received CE Mark approval to sell and market its intra-articular and epidural instruments across European Union. For more information please visit [www.medicalmilestone.com](http://www.medicalmilestone.com).

**Safe Harbor Statement**

*This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2019. The forward looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.*